Daily Medication Pearl: Daridorexant (Quviviq)


Daridorexant (Quviviq) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Medication Pearl of the Day: Daridorexant (Quviviq)

Indication: Daridorexant (Quviviq) is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance.


  • Dosing: The recommended dosage is 25 mg to 50 mg once per night, taken orally within 30 minutes before going to bed, with at least 7 hours remaining prior to planned awakening.
  • Dosage forms: Tablets 25 mg, 50 mg.
  • Adverse events: The most common adverse reactions, reported in ≥ 5% of patients treated with daridorexant and at an incidence ≥ than placebo, were headache and somnolence or fatigue.
  • Mechanism of action: The mechanism of action of daridorexant in the treatment of insomnia is presumed to be through antagonism of orexin receptors.The orexin neuropeptide signaling system plays a role in wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.
  • Manufacturer: Idorsia Pharma


  1. Approval [Rx ONLY] (idorsia.us)
  2. quiviviq image - Google Search
Related Videos
Image credit:  Gorodenkoff | stock.adobe.com
Sun Screen, Photosensitivity, Pharmacy | Image Credit: sosiukin - stock.adobe.com
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
Various healthy foods -- Image credit: New Africa | stock.adobe.com
LGBTQIA+ pride -- Image credit: lazyllama | stock.adobe.com
Modern pharmacy building facade with large window showcasing the interior, as seen from the street view, promoting a welcoming atmosphere for customers. Frontal view. Generative AI - Image credit: Karrrtinki | stock.adobe.com
Close up hands of helping hands elderly home care. Mother and daughter. Mental health and elderly care concept - Image credit:  ipopba | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.